Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.34 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1396157 | 0.82 | MAPK1 (0.35) | MCL1SRD5A2THRB | |
| SCHEMBL1662468 | 0.79 | MAPK1 (0.43) | MCL1SRD5A2THRB | |
| SCHEMBL870814 | 0.77 | MCL1 (0.33) | MCL1BCL2MEN1KMT2ATDP1 | |
| SCHEMBL2252786 | 0.72 | MCL1 (0.33) | MCL1BCL2MEN1KMT2ATDP1 | |
| SCHEMBL31352403 | 0.72 | CRBN (0.39) | MCL1BCL2SRD5A2 | |
| SCHEMBL1662124 | 0.71 | THRB (0.39) | MCL1BCL2SRD5A2THRB | |
| SCHEMBL428708 | 0.70 | — | — | |
| SCHEMBL31623264 | 0.70 | HSD11B1 (0.33) | MCL1 | |
| SCHEMBL8532532 | 0.70 | SRD5A2 (0.33) | MCL1BCL2SRD5A2 | |
| SCHEMBL14895840 | 0.70 | MCL1 (0.31) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189834-B1 | USE OF GABAA RECEPTOR REINFORCING AGENT IN PREPARATION OF SEDATIVE AND ANESTHETIC MEDICAMENT | HAISCO INNOVATIVE PHARMACEUTICAL PTE LTD (SG) | 2024-01-17 | — | — | EP | disclosed |
| US-10729666-B2 | Use of GABAA receptor reinforcing agent in preparation of sedative and anesthetic medicament | HAISCO CHENGDU PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-08-04 | — | — | US | disclosed |
| US-20170290781-A1 | USE OF GABAA RECEPTOR REINFORCING AGENT IN PREPARATION OF SEDATIVE AND ANESTHETIC MEDICAMENT | HAISCO INNOVATIVE PHARMACEUTICAL PTE. LTD. (SG) | 2017-10-12 | — | — | US | disclosed |
| EP-3189834-A1 | USE OF GABAA RECEPTOR REINFORCING AGENT IN PREPARATION OF SEDATIVE AND ANESTHETIC MEDICAMENT | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10729666-B2 | Use of GABAA receptor reinforcing agent in preparation of sedative and anesthetic medicament | GABRA1, GABRA5, GABRA2 | MCL1 4584/4885BCL2 4297/4885SRD5A2 1064/4885 |
| US-20170290781-A1 | USE OF GABAA RECEPTOR REINFORCING AGENT IN PREPARATION OF SEDATIVE AND ANESTHETIC MEDICAMENT | GABRA1, GABRA5, GABRA2 | MCL1 4584/4885BCL2 4297/4885SRD5A2 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.